Distinct gut microbiota but common metabolomic signatures between viral and MASLD HCC contribute to outcomes of combination immunotherapy
Distinct gut microbiota, but shared beneficial metabolites, particularly fecal acetate, are associated with durable response to combination immunotherapy and improved survival in both MASLD-HCC and V-HCC. Fecal acetate may serve as a potential biomarker and therapeutic target for optimizing HCC treatment.
Authors
- Pei-Chang Lee
- Hsien-Chen Mon
- Jiing‐Chyuan Luo (ORCID: https://orcid.org/0000-0003-4306-5464)
- I‐Cheng Lee (ORCID: https://orcid.org/0000-0002-9316-4682)
- Yi‐Hsiang Huang (ORCID: https://orcid.org/0000-0001-5241-5425)
- Ya‐Wen Hung
- Chieh-Ju Lee
- Yu-Lun Kuo
- Chen-Ta Chi
- Ming-Chih Hou
- Chi-Jung Wu
- Shih-Hsuan Chou
Institutions
- Fu Jen Catholic University (TW)
- National Yang Ming Chiao Tung University (TW)
- National Chung Hsing University (TW)
- Taipei Veterans General Hospital (TW)
- Tao Yuan General Hospital (TW)
Publication Details
- Journal
- Hepatology
- Published
- 2025-06-30
- DOI
- https://doi.org/10.1097/hep.0000000000001446
- Citations
- 7
- Primary Topic
- Gut microbiota and health
- Type
- article
- Field-Weighted Citation Impact
- 5.64